Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 142.05M P/E - EPS this Y 36.00% Ern Qtrly Grth -
Income -104.56M Forward P/E -1.11 EPS next Y 10.30% 50D Avg Chg -7.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -37.00%
Dividend N/A Price/Book 1.14 EPS next 5Y - 52W High Chg -75.00%
Recommedations 1.50 Quick Ratio 3.53 Shares Outstanding 48.34M 52W Low Chg 33.00%
Insider Own 10.76% ROA -55.38% Shares Float 37.31M Beta 1.05
Inst Own 53.43% ROE -134.14% Shares Shorted/Prior 4.45M/4.75M Price 2.98
Gross Margin - Profit Margin - Avg. Volume 428,048 Target Price 9.75
Oper. Margin - Earnings Date Nov 5 Volume 475,176 Change 3.47%
About BioAtla, Inc.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

BioAtla, Inc. News
12/20/24 BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
12/18/24 Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31
12/16/24 BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
12/10/24 BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
11/08/24 BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
11/07/24 3 Promising US Penny Stocks With At Least $90M Market Cap
11/07/24 BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
10/31/24 BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
10/30/24 BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake
10/20/24 BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025
10/09/24 BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
10/04/24 BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
10/01/24 BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
09/23/24 BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
09/16/24 BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
09/09/24 BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
09/04/24 Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky
08/28/24 BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
08/08/24 Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
08/01/24 BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
BCAB Chatroom

User Image Plungeprotectiongang Posted - 7 hours ago

$BCAB I think another email will help.

User Image PenkeTrading Posted - 18 hours ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Bioatla Inc. Is that bullish or bearish? $BCAB #RsiOversold #NASDAQ

User Image MrWick007 Posted - 1 day ago

$BCAB book value is $0.42?

User Image Plungeprotectiongang Posted - 1 day ago

$BCAB

User Image winners18 Posted - 1 day ago

$BCAB The presentation was done at adc summit in early nov!

User Image winners18 Posted - 1 day ago

$BCAB ➢ “NextGen CAB ADC platformo Minimizes off-tumor, on-target toxicity (CAB via elimination of TMDD)o Increased tolerabilityo Increased MTD o Significantly improved serum stabilityo Enhanced hydrophilicity, allowing for a higher DAR o Adaptable to different linkers and payloads➢ CAB Nectin4 ADC (BA3361) o IND approved in 1H/2024o Similar efficacy to EV in bladder, breast, and lung cancer modelso Superior efficacy to EV in pancreatic cancer modelso Glycosidase-sensitive linker broadens the number of potential clinical indicationso Clinical trials to start soon! ” This was presented just 2 weeks ago

User Image winners18 Posted - 1 day ago

$BCAB is the co going to shelf the cab clta4 and ror2 adc program? No mention of this 2 pipeline products today! Not sure y the co is issuing so few shares to get 10 million dollars. Very perplexed!

User Image BagholderTerminator Posted - 1 day ago

$BCAB Ooof. Well, the hopium made it fun while it lasted.

User Image TraderMark71 Posted - 1 day ago

$BCAB Blah Blah Blah, guess, guess, guess..... Not one person on here knows what the future holds. I'm just playing the game...

User Image grzegorz_soros Posted - 1 day ago

$BCAB buying more shares next week

User Image LabPsycho Posted - 1 day ago

$BCAB @ErnieWorthing84 a bit harsh but maybe. Jay taking a big hit on this as well as he purchased shares much higher than current price. How can they recover from trading down here now?

User Image ErnieWorthing84 Posted - 1 day ago

$BCAB Strong $GRTS vibes here

User Image Mugu Posted - 1 day ago

$BCAB bleeding out like a stuck pig

User Image HoHoHoHum Posted - 1 day ago

$BCAB looks like market has concluded this is going bk! Hope i am wrong.

User Image badiebalboa Posted - 1 day ago

$BCAB what happened, didnt they have money ? never trust this ceo again, RIP

User Image beentherebefor Posted - 1 day ago

$BCAB why raise only 9.2 million when you already have enough funding through 1st quarter 2026? could the warrants be incentive for a partnership

User Image HighClubSpeed Posted - 1 day ago

$BCAB wonder how much this thing netted Jay? Not a bad play for him even if we go to zero

User Image MrWick007 Posted - 1 day ago

$BCAB …in case of bankruptcy

User Image MrWick007 Posted - 1 day ago

$BCAB unless they’ve already factored in that once of bankruptcy they will be among the first in the queue to take back what they invested from the asset sale while wiping out shareholders?? Just a guess, haven’t checked the financials

User Image Rabinovich Posted - 1 day ago

$BCAB Warrants mean shorting central. Game over for this one, at least on the short to mid term. Sad for the SH.

User Image LabPsycho Posted - 1 day ago

$BCAB blew below the $1 by EOY

User Image eruizgon Posted - 1 day ago

$BCAB Furthermore, the shares that have been sold are because they have been bought by other people who expect to make a profit. I do believe that there will be a rebound when the fear disappears.

User Image ThumpSnap12 Posted - 1 day ago

$BCAB you can never trust earnings calls. Investing is not for the week

User Image eruizgon Posted - 1 day ago

$BCAB It is a hard blow for the shareholders but the fact that they continue investing in the project is good news

User Image LabPsycho Posted - 1 day ago

$BCAB @GwadaLuvM0n3y - You and hundreds of thousands of other biotech investors share the same sentiment. This is why I think the biotech sector is dead money for a few years, with just 1/25 being a 3Xer. BioGrifters have been $crewing over existing investors for over 2 yr now with dilutions. I am expecting a muted, if any, Jan-Feb 2025 effect.

User Image OldCarGuy Posted - 1 day ago

$BCAB

User Image GwadaLuvM0n3y Posted - 1 day ago

$BCAB there will be no reverse price action for months and months now.. Last Pharma company I invest in man... From a partnership deal to dilution... with no warning....

User Image LabPsycho Posted - 1 day ago

$BCAB IMO, While I think conditionally active biomolecules have potential, I have posted my concerns on BCAB for almost a year now - 1.The implied partnership for their clinical candidate(s) since last Dec that have not yet materialized, 2. the analyst Remy suggesting during a conference callJay should shelf the entire project last ~Jan 3. The seemingly IMO low energy of the management at the conference calls 4. Burry buying and selling after a small gain 5. Bristol Meyers Squibb publishing their own patents and papers on conditionally active molecules 6. Management not buying any shares the past ~ year at depressed prices. The writing was on the wall for quite some time IMO. With this dilution, at this time of year and with the biotech sector tanking tells you how desperate biotech companies are for cash.

User Image Ketakutan Posted - 1 day ago

$BCAB And they've done what they said they would try not to do, diluting shares... That's not the christmas present I was expecting...

User Image MrWick007 Posted - 1 day ago

$BCAB you were right all along!

Analyst Ratings
JMP Securities Market Outperform Sep 16, 24
JMP Securities Market Outperform May 23, 24
HC Wainwright & Co. Buy May 15, 24
JMP Securities Market Outperform Mar 28, 24
HC Wainwright & Co. Buy Mar 27, 24
JMP Securities Market Outperform Dec 5, 23
HC Wainwright & Co. Buy Nov 8, 23
JP Morgan Overweight Sep 25, 23
JP Morgan Overweight Aug 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MCBRINN SYLVIA Director Director Mar 28 Buy 2.35 4,000 9,400 19,125 01/19/24
MCBRINN SYLVIA Director Director Dec 26 Buy 2.33 4,000 9,320 15,125 12/26/23
SHORT JAY M PHD Chief Executive Offi.. Chief Executive Officer Dec 20 Buy 2.1382 50,000 106,910 1,439,283 12/20/23
STEINMAN LAWRENCE Director Director Dec 19 Buy 2.0524 20,000 41,048 38,459 12/19/23
MCBRINN SYLVIA Director Director Sep 08 Buy 2.54 2,000 5,080 11,125 09/13/23
SHORT JAY M PHD Chief Executive Offi.. Chief Executive Officer Mar 29 Buy 2.4721 40,800 100,862 1,412,387 03/30/23
Vasquez Christian See Remarks See Remarks Mar 28 Buy 2.3985 20,000 47,970 102,709 03/29/23
MCBRINN SYLVIA Director Director Dec 19 Buy 8.3279 3,700 30,813 9,125 12/19/22
SHORT JAY M PHD Chief Executive Offi.. Chief Executive Officer Aug 12 Buy 7.8406 26,350 206,600 1,396,556 08/15/22
SHORT JAY M PHD Chief Executive Offi.. Chief Executive Officer Jun 21 Buy 2.85 69,390 197,762 1,375,982 06/23/22
WALDRON RICHARD A Chief Financial Offi.. Chief Financial Officer Nov 30 Sell 23.49 14,190 333,323 134,469 12/07/21
Vasquez Christian See Remarks See Remarks Nov 30 Sell 23.49 1,979 46,487 25,259 12/07/21
Smith Scott Andrew President President Nov 30 Sell 23.49 4,090 96,074 345,656 12/07/21
Sievers Eric Chief Medical Office.. Chief Medical Officer Nov 30 Sell 23.49 1,124 26,403 91,506 12/07/21
SHORT JAY M PHD Chief Executive Offi.. Chief Executive Officer Nov 30 Sell 23.49 47,622 1,118,641 1,320,811 12/07/21
WALDRON RICHARD A Chief Financial Offi.. Chief Financial Officer Nov 22 Sell 25.23 13,333 336,392 153,258 11/30/21
Vasquez Christian See Remarks See Remarks Nov 22 Sell 25.23 2,541 64,109 27,880 11/30/21
Smith Scott Andrew President President Nov 22 Sell 25.23 1,580 39,863 350,145 11/30/21
Sievers Eric Chief Medical Office.. Chief Medical Officer Nov 22 Sell 25.23 434 10,950 92,740 11/30/21
SHORT JAY M PHD Chief Executive Offi.. Chief Executive Officer Nov 22 Sell 25.23 57,640 1,454,257 1,383,868 11/30/21